Drug intelligence / Profile preview

amifostine + carboplatin

Development stage: Unknown
Lead developer: U.S. Bioscience
Modality: Small Molecules
Administration: Intravenous

Overview

A combination therapy where amifostine (WR-2721) is used as a cytoprotective agent alongside carboplatin chemotherapy. Amifostine is a thiol compound that selectively protects normal tissues from chemotherapy-induced toxicity without compromising anti-tumor efficacy. When used with carboplatin, it has been shown to reduce thrombocytopenia duration and hospitalization needs.

Targets

Pt-DNA adduct (DNA-oxaliplatin adduct)

Beyond the preview

Go deeper on amifostine + carboplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amifostine + carboplatin.

Explore the full profile